Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: Effects on stability of anticoagulant therapy and frequency of hemorrhage

Terapevticheskii Arkhiv

Volumn 83, Issue 6, 2011, Pages 59-65

  Vorobyeva, N M ^a   Panchenko, E P ^a   Dobrovolsky, A B ^a   Titaeva, E V ^a   Khasanova, Z B ^a   Konovalova, N V ^a   Postnov, A Yu ^a   Kirienko, A I ^b  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Hemorrhagic complications; Pharmacogenetics; Polymorphisms of genes CYP2C9 and VKORC1; Venous thromboembolic complications; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; RUSSIAN FEDERATION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MOSCOW; POLYMORPHISM, GENETIC; VENOUS THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 79960534623     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kearon C., Kahn S. R., Agnelli G. et al. Antithrombotic therapy for venous throm-boembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(Suppl):454S-545S. (Pubitemid 351892971)
2. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008;29:2276-2315.
3. Rettie A. E., Jones J. P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 2005;45:477-494. (Pubitemid 40267790)
4. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96(5):1816-1819. (Pubitemid 30661066)
5. Yin T., Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - Rationale and perspectives. Thromb. Res. 2007;120(1):1-10. (Pubitemid 46601582)
6. Mortdani M., Fu L., Selby R. et al. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin. Biochem. 2006;39(6):606-612.
7. Sconce E. A., Khan T. L., Wynne H. A. et al. The impact of CYP2C9 and VKORC1 polymorphism and patients characteristics upon warfarin dose requirements: proposal for a hew dosing regimen. Blood 2005;106:2329-2333. (Pubitemid 41510803)
8. Ansell J., Hirsh J., Poller L. et al. The Pharmacology and Management of the Vitamin K Antagonists. The Seventh AC-CP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-233S. (Pubitemid 39297955)
9. Gaikovitch E., Cascorbi L, Mrozikiewicz P. M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 2003;59:303-312. (Pubitemid 37100349)
10. Sullivan P. W., Aranl T. W., Ellis S. L., Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;24(10):1021-1033. (Pubitemid 44497473)
11. Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a Hu-GEnet systematic review and meta-analysis. Genet. Med. 2005;7(2):97-104. (Pubitemid 40261834)
12. You J. H., Chan F. W., Wong R. S., Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb. Haemost. 2004;92(3):590-597. (Pubitemid 39248016)
13. Schulman S., Kearon C., Kakkar A. K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009;361:1-11.
14. Agnelli G., Callus A., Goldhaber S. Z. et al. Treatment of proximal deepvein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY59-7939): the ODIXa DVT (oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116:180-187. (Pubitemid 47057524)
15. Buller H. R., Lensing A. W., Prins M. H. et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112:2242-2247.